- Fecha de presentación
- 18 July 2006
- Palabras clave
- Países de daño
- Situación actual
-
Rechazada
- Sector
- NCP
Acusaciones
Ratiopharm, a pharmaceuticals company and major producer of generic drugs, has allegedly engaged in unethical marketing practices, including bribing doctors and pharmacists in Belgium, Canada, Spain, Estonia and Germany.
Directrices relevantes de la OCDE
Resultado
In December 2006, the German NCP rejected the second complaint against Ratiopharm. The NCP argued that the complaint would had to be dealt with by the NCP of the country where the alleged misbehaviour occurred, i.e. Belgium, Canada, Estonia, and Spain.
Transparency International and the NCP met informally in March 2007. Again, the NCP insisted it could not accept the Ratiopharm case and refused to forward it to the relevant NCPs. The NCP claimed its “hands were tied”.
Transparency International maintains that the alleged misbehaviour emanates from Ratiopharm’s German headquarters to other countries. Therefore, the German NCP should take the lead in handling the complaint. In addition, the NCP’s refusal to forward the case to the other relevant NCPs inspires little faith in the NCP’s offer to assist informally.
Más detalles
- Demandante
- Empresa en infracción
- Demandantes
- Personas afectadas
- Fecha rechazada / concluida
- 1 December 2007
Quejas relacionadas
- Gresea & Transparency International Germany vs Ratiopharm
- Transparency International Germany vs. Ratiopharm